BUZZ-血癌药物试验失败,Apollomics业绩下滑

Reuters
Dec 20, 2024

((自动化翻译由路透提供,请见免责声明 ))

12月20日 - ** 生物技术公司Apollomics 股价盘前下跌约30%至6.63美元 ** 该公司称,在一项晚期试验中,其试验性血癌疗法与化疗联合使用未能显示出 (link) 延长生存期对单独化疗有利的效果

** Apollomics公司正在复发或难治性急性髓性白血病患者中测试这种名为uproleselan的疗法$(AML.UK)$

** 急性髓性白血病是一种始于骨髓并影响白细胞的血癌。

** 截至上次收盘,该公司股价年累计下跌约 90

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10